Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.01 – $0.25
5% from low
Exchange
OTC Link
CS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8M | $4.7M | $7.6M | $6.9M | $2.8M | $3.8M | $2.1M | $5.8M |
| Cost of revenue | $11.0M | $1.6K | $102.3K | $6.6M | $10.3M | $4.0M | $3.7M | $3.4M |
| Gross profit | −$9.3M | $4.7M | $7.5M | $315.8K | −$7.5M | −$3.0M | −$1.6M | $2.3M |
| Gross margin | -521.0% | 100.0% | 98.6% | 4.6% | -273.6% | -80.7% | -76.5% | 40.3% |
| R&D | $11.0M | $16.6M | $13.7M | $6.6M | $10.3M | $5.7M | $1.8M | $143.9K |
| Operating income | −$11.0M | −$17.0M | −$16.7M | −$9.4M | −$22.4M | −$13.6M | −$15.5M | −$86.3M |
| EBITDA | $0 | −$17.2M | −$16.6M | −$3.4M | −$13.0M | −$9.0M | −$13.8M | −$82.2M |
| Net income | −$11.0M | −$17.0M | −$16.7M | −$3.3M | −$13.2M | −$9.2M | −$13.9M | −$86.4M |
| Net margin | -619.4% | -363.6% | -220.9% | -48.4% | -478.1% | -242.7% | -670.2% | -1500.6% |
| EPS (diluted) | -0.02 | -0.02 | -0.02 | -0.00 | -0.01 | -0.01 | -0.01 | -0.05 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $35M | $-0.02 | $-0.02–$-0.02 | 1 |
| 2027 | $74M | $-0.01 | $-0.01–$-0.01 | 1 |
| 2028 | $139M | $0.01 | $0.01–$0.01 | 1 |
| 2029 | $38M | $0.03 | $0.02–$0.04 | 1 |
Forward consensus · source: Financial Modeling Prep
BOTANIX PHARMACEUTICALS
No one on the platform currently holds BXPHF.
No tracked institution reports a position in BXPHF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2016-06-16 | 1000-for-3333reverse |
| 2014-01-24 | 1-for-50reverse |
| 2004-08-23 | 1-for-4reverse |
No one on the platform has traded BXPHF yet.
| $155M |
| — |
| JWCTFJW (Cayman) Therapeutics Co. Ltd | $0.24 | +0.00% | $99M | — |
| KNTPFKintor Pharmaceutical Limited | $0.34 | +0.00% | $160M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 8.8× sales vs its 48.4× historical median P/S.
Fair value ≈ $0.13 · price $0.02 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.